Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies
Together, these findings support affinity-matured CD72 nanoCARs as a potential immunotherapy product for CD19-refractory B-cell cancers. Our results also suggest that for B-ALL in particular, CD72 may be a preferable second-line immunotherapy target over CD22.
Authors
- Constance M. Yuan (ORCID: https://orcid.org/0000-0002-2601-3665)
- William C. Temple
- Akul Naik
- Szu-Ying Chen
- Ons Zakraoui
- Marcela V. Maus (ORCID: https://orcid.org/0000-0002-7578-0393)
- Veronica Steri (ORCID: https://orcid.org/0000-0003-2499-6618)
- Samir Sunil Parekh (ORCID: https://orcid.org/0000-0001-9694-8469)
- Fernando Salangsang
- Paul Phojanakong
- Martinez-Lopez Joaquin
- Amrik S. Kang (ORCID: https://orcid.org/0000-0003-0445-5654)
- A. Verma
- Sarah Aminov
- Adila Izgutdina (ORCID: https://orcid.org/0000-0002-3296-3261)
- M Li
- Arun P. Wiita (ORCID: https://orcid.org/0000-0002-7465-6964)
- Emilio Ramos
- Juan A. Cámara (ORCID: https://orcid.org/0000-0001-7494-1127)
- Matthew A. Nix (ORCID: https://orcid.org/0000-0001-7741-5368)
- Daniel Gil-Alós (ORCID: https://orcid.org/0009-0002-8504-2842)
- N. Shah
- Isa Tariq
- Srabani Sahu (ORCID: https://orcid.org/0009-0002-3667-3592)
- Tasfia Rashid
- H Takamatsu
- Sujata Walunj
- Bonell Patiño-Escobar
- Rebecca C Larson
- Hao-Wei Wang
- Huimin Geng
- Antonio Valeri
- Haley Johnson
- Christopher Carpenter
Institutions
- Kanazawa University (JP)
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Research Institute Hospital 12 de Octubre (ES)
- Massachusetts General Hospital (US)
- Spanish National Cancer Research Centre (ES)
- Hospital Universitario 12 De Octubre (ES)
- Parker Institute for Cancer Immunotherapy (US)
- Chan Zuckerberg Initiative (United States) (US)
- Palo Alto Institute (US)
- UCSF Benioff Children's Hospital (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Arc Research Institute
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-012013
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Multiple Myeloma Research Foundation
- Alex's Lemonade Stand Foundation for Childhood Cancer
- California Institute of Regenerative Medicine
- National Institutes of Health
- University of California, San Francisco
- Instituto de Salud Carlos III
- National Cancer Institute
- NIH Clinical Center